Log in

  • Home
  • Advancing Care for People Living with Moderate-to-Severe Atopic Dermatitis

Advancing Care for People Living with Moderate-to-Severe Atopic Dermatitis

  • 06/15/2021
  • 12:00 PM - 1:00 PM
  • Zoom


Eric Simpson MD MCR - Oregon Health & Science University

Slide Deck

CME Information

Activity Description
Over the past decade, the understanding of atopic dermatitis (AD) pathogenesis has evolved, giving way to numerous potential therapeutic targets. During this time, Janus kinase (JAK) inhibitors—a new class of medications—have also emerged. While the JAK-signal transducer and activator of transcription (JAK-STAT) pathway did not seem to be an obvious target early on, JAK inhibitors are likely to be the next generation of agents FDA approved for the treatment of moderate to severe AD. Indeed, JAK inhibitors are demonstrating benefit across multiple dermatologic diseases and constitute a promising frontier for dermatologic therapy overall.

In this activity, based on a recent live web broadcast, our expert faculty examine the complex pathogenesis that underlies AD, focusing on the rationale for development of novel therapeutic approaches. In addition, key information (eg, mechanism of action, side-effect profiles, and dosing) for these new and emerging agents for moderate to severe AD will be provided, as well as the most up-to-date efficacy and safety data and practical considerations for clinical use.

Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers (NPs, PAs), nurses, and other clinicians involved in the management of atopic dermatitis.

Educational Objectives
Upon completion of this accredited CE activity, participants should be better able to:

  • Recognize recent insights into the pathogenesis of atopic dermatitis (AD) that have led to the development of new molecules targeting key cytokine signaling pathways
  • Evaluate recent safety and efficacy data related to emerging treatment options for moderate to severe AD, identifying potential implications for patient care
  • Develop strategies to identify candidates for newer therapeutic options and overcome barriers to achieving treatment goals in patients with moderate to severe AD

Physician Continuing Medical Education
ACCMEMedical Learning Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is developed with our educational partner, PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Pfizer.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and 1.0 Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Professional Development
Medical Learning Institute, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Faculty Disclosures
Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
Department of Dermatology
George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan I. Silverberg, MD, PhD, MPH, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for AbbVie Inc.; Afyx; Arena Pharmaceuticals, Inc.; Asana BioSciences, LLC; BiomX; Bluefin; Bodewell; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant Sciences, Inc.; Dermira, Inc.; Eli Lilly and Company; Galderma; GlaxoSmithKline; Incyte; Kiniksa Pharmaceuticals, Ltd.; LEO Pharma Inc.; Luna Pharmaceuticals; Menlo Therapeutics Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; RAPT Therapeutics; Regeneron; and sanofi-aventis U.S. LLC.
Grant/Research Support from Galderma and Pfizer, Inc.
Speakers Bureau participant with Eli Lilly and Company; Pfizer, Inc.; Regeneron; and sanofi-aventis U.S. LLC.

Eric Simpson, MD, MCR
Professor of Dermatology
Oregon Health & Science University
Portland, Oregon

Eric Simpson, MD, MCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Dermira, Inc.; Forte Biosciences, Inc.; Genzyme Corporation; Incyte; LEO Pharma Inc.; Lilly; Pfizer, Inc.; Regeneron Pharmaceuticals Inc.; and sanofi-aventis U.S. LLC. Grant/Research Support from Incyte; Kyowa Kirin Co., Ltd; LEO Pharma Inc.; Lilly; Merck & Co., Inc.; Pfizer, Inc.; and Regeneron Pharmaceuticals Inc.

About ODS

ODS is a non-profit organization with a mission to continually improve dermatologic care through education, advocacy, and service. We represent nearly 300 dermatologists, physicians assistants, and nurse practitioners in Oregon and the region.

Contact Us

Copyright © Oregon Dermatology Society
Powered by Wild Apricot Membership Software